Publicacións en colaboración con investigadores/as de Complejo Asistencial Universitario de León (22)

2024

  1. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study

    Clinical and Translational Oncology

  4. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2023

  1. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

2021

  1. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial

    Molecular Oncology, Vol. 15, Núm. 1, pp. 43-56

  2. Electronic health records and patient registries in medical oncology departments in Spain

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 2099-2108

  3. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  4. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 140-148

  2. Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

    Therapeutic Advances in Medical Oncology, Vol. 12

2019

  1. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

    Oncologist, Vol. 24, Núm. 4, pp. 491-497

2017

  1. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study

    Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9

  2. Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

    Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1537-1542

2014

  1. Breast cancer management in the elderly

    Clinical and Translational Oncology, Vol. 16, Núm. 4, pp. 351-361

  2. Clinical guideline SEOM: cancer of unknown primary site

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1091-1097

2011

  1. A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study

    Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691

  2. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)

    Investigational New Drugs, Vol. 29, Núm. 5, pp. 1038-1044

  3. Management of patients with metastatic breast cancer

    Advances in Therapy, Vol. 28, Núm. SUPPL. 6, pp. 50-65